AI Article Synopsis
- Long-acting injectable (LAI) antipsychotics, like aripiprazole lauroxil, are crucial for treating schizophrenia, offering various formulations and dosing options.
- Advances in formulation technology have improved the safety and effectiveness of LAIs, yet most reviews have overlooked this aspect in clinical practices.
- The article highlights the importance of proper injection techniques for LAIs, emphasizing the need to resuspend the drug and inject quickly to ensure optimal delivery.
Article Abstract
Long-acting injectable (LAI) antipsychotics are an important treatment option for patients with schizophrenia. Advances and variability in formulation technology have provided several LAI antipsychotic treatment options for schizophrenia, with a wide range of doses and dose intervals. However, clinical reviews of LAIs have not focused on formulation development despite its clinical relevance to injection safety and technique. This article reviews the relationship between formulation technology and clinical practices for LAIs, with a focus on aripiprazole lauroxil, a long-acting atypical antipsychotic indicated for the treatment of schizophrenia. The formulation developed for aripiprazole lauroxil is an aqueous-based suspension suitable for use as a prefilled syringe that, after injection, will release aripiprazole slowly into the plasma. The clinical relationship between the aripiprazole lauroxil formulation and proper injection techniques is explained, including why tapping and shaking the syringe to resuspend the drug particles and rapid injection speed are key steps for best injection practices for this formulation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/PRA.0000000000000376 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Appropriate use of single-dose injectable aripiprazole lauroxil in the treatment of schizophrenia.
Ment Health Clin
December 2024
(Corresponding author) Associate Professor, Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Georgia, Athens, GA,
Introduction: Single-dose injectable aripiprazole lauroxil (SDIAL) is used with long-acting injectable (LAI) aripiprazole lauroxil in the treatment of schizophrenia. SDIAL can be used to either initiate treatment or supplement during maintenance when follow-up doses are not given within labeling recommendations. The primary objective was to determine the usage and appropriateness of SDIAL between the initiation and the maintenance supplementation use in a Medicaid database.
View Article and Find Full Text PDFLong-Acting Injectable Antipsychotic Initiation in Child and Adolescent Patients with Psychiatric Disorders.
J Child Adolesc Psychopharmacol
August 2024
UPMC Western Psychiatric Hospital, Pittsburgh, Pennsylvania, USA.
There are currently no long-acting injectable antipsychotics (LAIAs) that are approved by the Food and Drug Administration for use in child and adolescent patients, however these agents are used off-label for the treatment of various psychiatric disorders. This study aims to describe the initiation and maintenance dosing strategies of LAIAs in child and adolescent psychiatry inpatients. This was a single-site retrospective chart review of patients less than 18 years of age initiated on an LAIA during an acute psychiatric hospitalization between October 1, 2015, and October 31, 2022.
View Article and Find Full Text PDFInitiating Aripiprazole Lauroxil: Post Hoc Analysis of Safety and Tolerability of 1-Day and 21-Day Regimens.
J Clin Psychiatry
August 2024
Alkermes, Inc, Waltham, Massachusetts.
Article Synopsis
- Aripiprazole lauroxil (AL) is a long-acting injectable antipsychotic that can be initiated using either a 1-day or 21-day regimen, and this study analyzed their safety and tolerability.
- The post hoc analysis showed comparable adverse event rates between both regimens, with most events being mild, although some specific side effects (like injection site reactions and akathisia) were noted.
- The findings indicate that both initiation approaches are similarly safe, suggesting the importance of involving patients in selecting their treatment plan for schizophrenia.
A 16-Year-Old Male with Autism Spectrum Disorder, Psychosis, and Refusal to Accept Any Oral Medication: A Case Report and Use of Long-Acting Injectable Aripiprazole Lauroxil.
J Child Adolesc Psychopharmacol
July 2024
Winnebago Mental Health Institute, Winnebago, Wisconsin, USA.
Functioning and Cognition in Patients with Schizophrenia After Initiating Treatment with Aripiprazole Lauroxil: Secondary Outcomes and Post Hoc Analysis.
Innov Clin Neurosci
March 2024
Drs. Claxton, McGrory, Wang, and Yagoda and Ms. Gasper are with Alkermes, Inc. in Waltham, Massachusetts.
Background: Clinical practice guidelines support efforts to improve functioning in patients with schizophrenia. Discrepancies in the perception of cognitive status between clinicians, patients with schizophrenia, and their caregivers have been associated with impaired functional abilities in patients; medication side effects might worsen both cognition and daily functioning. We assessed daily/social functioning and cognition in stable patients with schizophrenia who switched to the long-acting injectable (LAI) antipsychotic aripiprazole lauroxil (AL).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!